REGENXBIO to Participate in Upcoming Investor Conferences
News related to:REGENXBIO Inc · 1 min read
ROCKVILLE, Md., Sept. 8, 2026 /CourierPR/ -- REGENXBIO Inc., a biotechnology company based on the potential of gene therapy, will participate in two upcoming investor conferences in New York City. The company will host a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, at 8:30 a.m. Eastern Time. The event will take place in New York, NY.
On Wednesday, September 16, REGENXBIO will also present at the Morgan Stanley 24th Annual Global Healthcare Conference. The company’s representative will again engage in a fireside chat at 8:30 a.m. ET, also held in New York.
Attendees of these conferences can access live webcasts of the events through the Investors section of REGENXBIO's website, which is available at www.regenxbio.com. The webcasts will remain available for approximately 30 days after the respective events.
REGENXBIO Inc. is at the forefront of AAV (adeno-associated virus) gene therapy, developing one-time treatments for rare and retinal diseases. The company’s late-stage pipeline includes several promising therapies. RGX-202 is in development for the treatment of Duchenne muscular dystrophy, while clemidsogene lanparvovec (RGX-121) and RGX-111 are being evaluated for the treatment of MPS II and MPS I, respectively, in collaboration with Nippon Shinyaku. Additionally, surabgene lomparvovec (ABBV-RGX-314) is being advanced for the treatment of wet age-related macular degeneration and diabetic retinopathy in partnership with AbbVie.
Since its founding in 2009, REGENXBIO has treated thousands of patients with its AAV platform, including those who have received Novartis’ ZOLGENSMA® and ITVISMA®. The company’s investigational gene therapies hold the potential to transform healthcare, offering curative treatments for millions of people.
These upcoming presentations are part of REGENXBIO’s ongoing efforts to engage with the investment community and share updates on its advancements in gene therapy. By participating in these conferences, the company aims to provide investors with the latest insights into its research and development pipeline and strategic plans.